Prostate Cancer Research Paper

Prostate Cancer is a disease in which there is an uncontrolled growth of cells that lines the ducts of the prostate gland. The abnormal cells can spread throughout the prostate and nearby organs, such as the seminal vesicles. If not caught early they can spread (metastasized) to other organs of the body through the lymph or blood stream. (“...Treatment...” 13) Prostate Cancer can be like a silent killer. Some may show signs and symptoms of this disease while others may not. Some symptoms may include frequent urination, blood in the urine or semen, delayed or slowed start of urinary stream and dribbling or leakage of urine. Diagnosis testing for Prostate Cancer are digital

The best treatment for the prevention of cancer is early detection. In September, The National Football League (NFL) teamed up with Cancer Treatment Centers of America and LabCorp to educate men about the risks of prostate cancer and to offer Prostate Specific Antigen (PSA) screening.

TREATMENT of localized prostate cancer usually includes prostatectomy and radiation therapy, occasionally augmented with hormonal therapies. However, Fu et al., (2012) have noted that recurrence of prostate cancer occurs in about 15% of patients within 5 years after prostatectomy and in about 40% patients within 10 years. Although, more than 70% of patients are expected to survive for more than 10 years after prostatectomy, radiation or hormone therapy, Cooperberg et al.,(2010) argued that localized prostate cancer patients with intermediate or high risk scores have higher mortality rate after these treatments. With chemotherapies as the existing treatment options for metastatic prostate cancers, patients are expected to have only a median survival of 12-15 months. Bono et al.,(2006). However, most of these traditional treatments are invasive and riddled with adverse side effects. Therefore, novel therapies are on high demand for the treatment of the malignant and recurrent forms of prostate cancer after these

Regardless of its commonness, a comprehension of the atomic modifications influencing the improvement, movement, and treatment of the ailment was to a great extent lacking as of not long ago.Regardless of its transcendence, a comprehension of the nuclear changes impacting the headway, movement, and treatment of the disease was for the most part missing up to this point. Fast advances in sub-atomic procedures in the previous decade have seen a sensational increment in our comprehension of the part sub-atomic changes play in prostate malignancy. The sub-atomic changes found have demonstrated that prostate growth advancement

Prostate cancer is the most prevalent nonskin cancer among men in the United States and is the second leading cause of cancer death in men. While prostate cancer is most regularly diagnosed in men at the age of 65 years and older, the occurrence can begin at 50. One in 6 men will be diagnosed with prostate cancer during their lifetime. As researchers explore this form of cancer; men also need to know it’s essential to understand early prostate cancer is treatable. By these patients exploring these insights and investigating the lived experience of older men, it can provide a positive coping mechanisms.

The disease epidemiology has also been researched in different sub-populations. In a cohort of men that underwent screening for prostate cancer, Peyronie's disease prevalence was 8.9%. Significantly higher prevalence of 15.9% is seen in men after radical prostatectomy. Furthermore, in men evaluated for erectile disfunction, Peyronie's disease was found in 7.9% of individuals. Diabetes has also been identified as a potential risk factor for the development of this condition.

Traditionally men are expected to be the stronger sex, the breadwinner, the hunter- gatherer, but when it comes to prostate cancer men can feel powerless. Hormone therapies are used to chemically castrate men as a means of treating the cancer through more personalised medicine. However, when the cancer becomes refractory, Docetaxel is used as a first line chemotherapy to treat metastatic castration resistant prostate cancer in combination with Prednisolone. Mr. Smith (pseudonym) was diagnosed with Advanced Metastatic Prostate Cancer which was controlled by Abiraterone Acetate (an androgen biosynthesis inhibitor and works by inhibiting the CYP17 enzyme that is used to feed the cancer) until the cancer started to progress, and was

Treatment options for advanced prostate cancer may include hormone therapy, radiation therapy, orchiectomy (the surgical removal of the testicles), and possibly chemotherapy. Treatment will usually cause the PSA to drop significantly. Over time, however, treatment ceases to be effective as the cancer continues to progress. This is typically associated with a new rise in the PSA level. After the treatment stops being effective, the cancer is fatal. As of the time this article was written approximately 27,000 men a year are expected to die in the U.S. from advanced prostate cancer.

Cancer is a word that any normal person fears. It is a word that brings bad memories and an often unforgiving results to many people around the world each year. In the summer of 1997, 23 year old Chicago native Erik Strand gave himself a testicular exam, and discovered what seemed to feel like a ball bearing protruding from his right testicle. It was painless and did not cause discomfort at the time. Over the next few weeks, he noticed the testicle getting larger and harder. The following few weeks included visits to his primary care physician, an ultrasound of his testicle, and several blood tests. In the summer of 1997, Erik

The 21st century has seen great progress in diagnosing and treating many types of cancers. Advancements in the medical field are helping more people discover their cancer earlier. Doctors are treating more Stage 1 and Stage 2 cancers than ever before. Survival rates are increasing due to early discoveries of tumors. In addition, better medicine and new technology has raised the survival rates of most cancers. More and more people are living beyond treatment and the number of survivors is only expected to increase as time continues.

The risk of prostate cancer is the greatest for American males. The symptoms of prostate cancer are; frequent urination especially at night, difficulty starting urination or holding back urine, weak or interrupted flow of urine, painful or burning urination, difficulty having an erection, painful ejaculation, blood in urine or semen, and frequent pain or stiffness in the lower back, hips, or upper thighs. Prostate cancer is diagnosed by digital rectal examination, prostate-specific antigen blood test, and transrectal ultrasound. Also, tissue biopsy, microscopic examination, lymphography, bone scans, MRI and CT scans are used to confirm a diagnosis. Prostate cancer is treated is based upon the stage of the disease. Some of the various treatments

During the period, there were about 7,000 cases of prostate cancer, of which 934 were fatal.

Prostate cancer treatment is explored by three different solutions: surgical, radiation, and hormonal treatment. The surgical removal of prostate cancer has for many years been the most common treatment of the disease. (Fuller, 2006) This process has been very controversial. Many argue that surgery is the only real solution for permanently curing prostate cancer. Other challengers claim that the central influence of surgery is to produce incontinence and impotence without any clear evidence, compared to other forms of treatment, that it actually lengthens men’s lives. (Fuller, 2006) After surgery, radiation is the most frequent treatment of prostate cancer in the United States. Its popularity increased in the 1960s. Radiation works by disrupting

is evidently written for oncologists and practitioners dealing with treatment plans for patients with any type of cancer, however, specifically those with prostate cancer. It should help with the assessment of the effectiveness of aggressive treatment in more depth before administering it as an early treatment to stop metastases. This article is also a great reflection of the journal that ‘covers all aspects of prostatic diseases, in particular prostate cancer’, indicating its usual audience are also those from the medical community.

The American Cancer Society has reported that 1 in 6 men will develop prostate cancer throughout their lifetime. There will be an expected 242,000 new cases diagnosed this year resulting in about 30,000 deaths from prostate cancer, which makes it the second leading cause of cancer death in American men. Prostate cancer is increasing in numbers and causing many deaths around the world. According to the American Cancer Society, prostate cancer is usually a very slow developing cancer. Prostatic Intraepithelial neoplasia or (PIN) is a condition in which the cells inside the prostate have started to grow abnormally. Scientists count the abnormal amount of cells under a microscope and diagnose the level of abnormal cell growth. High levels of PIN